摘要
目的 检测肝癌病人血浆和肝癌组织中血栓调节蛋白 (TM )的表达 ,探讨TM与肝癌临床病理特征的关系。方法 用酶联免疫吸附夹心法检测 45例肝癌和 6例肝良性占位病人手术前后的血浆TM水平 ;用免疫组织化学法检测肝癌及肝良性占位组织中的TM蛋白表达水平。结果 术前肝癌组血浆TM水平 ( 10 .2± 5 .7)ng/mL明显高于肝良性占位组 ( 6.1± 2 .2 )ng/mL和正常人对照组 ( 5 .7± 1.0 )ng/mL ,P <0 .0 5 ;术前TM血浆水平肝癌伴门静脉癌栓组 ( 6.9± 4.5 )ng/mL和多发肝癌结节组 ( 8.1± 4.6)ng/mL明显低于无门静脉癌栓组( 11.4± 5 .6)ng/mL和单发肝癌结节组 ( 11.5± 5 .9)ng/mL ,P <0 .0 5 ;40例肝癌病人肝癌切除术前TM水平( 10 .8± 5 .3 )ng/mL与肝癌切除术后 ( 7.6± 4.2 )ng/mL相比差异显著 ,P <0 .0 5。肝良性占位组术前与术后相比差异无显著性 ,P >0 .0 5。肝癌组织中TM蛋白表达阳性的病人术前血浆TM水平明显高于TM表达阴性者 ,P <0 .0 5 ;而术后血浆TM水平两者则无显著性差异 ,P >0 .0 5。结论 肝癌病人血浆中TM水平升高 。
Purpose: To detect the thrombomodulin(TM) level in patients with hepatocellular carcinoma (HCC) and explore its relation to the clinicopathological futures of HCC. Methods: 45 cases of patients with HCC, 6 cases of patients with benign liver occupying lesions(BLOL) and 10 adult control were enrolled in this study. Pre-and-postoperative plasma TM level of patients with HCC and (BLOL) was measured by enzyme linked immunosorbent assay, and the expression of TM in human HCC tissues was determined by immunohistochemistry assay. Results: The preoperative plasma TM level of patients with HCC(10.2 ± 5.7) ng/mL was significantly higher than that of those patients with BLOL(6.1 ± 2.2) ng/mL and that of normal control(5.7 ± 1.0) ng/mL, respectively (P 0.05). The preoperative plasma TM level of patients with single HCC(11.5 ± 5.9) ng/mL or no portal vein tumor thrombus(PVTT) (11. 4 ± 5.6) ng/mL was significantly higher than that of those patients with multiple HCC(8.1 ± 4.6) ng/ML or PVTT (6.9 ± 4.5) ng/mL, respectively (P 0.05). There was also no significant difference between the plasma TM level and other clinicopathological futures. Conclusions: Plasma TM increases in patients with HCC and correlates the formation of PVTT.
出处
《复旦学报（医学版）》
EI
CAS
CSCD
北大核心
2003年第1期9-12,共4页
Fudan University Journal of Medical Sciences
基金
973国家重点基础研究发展规划项目 (G19980 5 12 11)
上海市"医苑新星"资助项目
